Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2008

View Archived Issues

Sanofi-aventis reports Q2 highlights

Santhera provides update on idebenone for the treatment of Friedreich's ataxia

KUR-212 follow-up results of phase IIa trial in patients with burns requiring mesh grafting

Enrollment in phase IIb clinical trial for I-vation TA (MK-0140) suspended

New delta opioid receptor antagonist with antitussive activity identified at Toray

Bioavailability similar with ritonavir tablet and capsule formulations

Study shows long-term efficacy of tipranavir-ritonavir treatment for children with AIDS

CASTLE data on atenovir/ritonavir, lopinavir/ritonavir analyzed by gender, race and renal effects

AstraZeneca: Q2 regulatory and development update

Aloe extract UP-780 upregulates adiponectin expression, reduces HbA1c

Novel antiviral, antibacterial agents disclosed in recent patents

New compounds for treatment of inflammation revealed in patent literature

Recent patents disclose new anticancer compounds

NeuroSearch reports positive results from TIPO-2 human metabolic study of tesofensine

FDA grants marketing approval to Gilead's Viread for chronic hepatitis B

FDA issues approvable letter for NDA for Kynapid in atrial fibrillation

Oncolytics completes dose escalation in REO 010 clinical trial of Reolysin and docetaxel

Enrollment completed in phase IIa study of brostallicin in soft tissue carcinoma

Fresenius Kabi completes acquisition of Dabur Pharma

Preclinical data on memogain, a galantamine prodrug, reported by Galantos

ErbB3 antagonist MM-121 begins phase I trial

Phase III study of Trizytek meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...